Pharmaceutical

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval

MEDI-0618 is under clinical development by AstraZeneca and currently in Phase I for Migraine.

Jun 18, 2024 - 04:00
MEDI-0618 is under clinical development by AstraZeneca and currently in Phase I for Migraine.
Read the original article

Tags:

Previous Article

OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): ...

Next Article

DFV-890 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MDMA therapy wait goes on as FDA panel rejects Lykos’ PTSD treatment

MDMA therapy wait goes on as FDA panel rejects Lykos’ P...

Jun 6, 2024

Expert analysis: the latest in HIV research and clinical trials 

Expert analysis: the latest in HIV research and clinica...

Jan 3, 2024

Darovasertib by Ideaya Biosciences for Colorectal Cancer: Likelihood of Approval

Darovasertib by Ideaya Biosciences for Colorectal Cance...

Nov 2, 2023